Therapies on the Horizon for Diabetic Kidney Disease

Current Diabetes Reports

Volumn 15, Issue 12, 2015, Pages

  Khan, Sadaf S ^a   Quaggin, Susan E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Bardoxolone; Diabetic nephropathy; JAK STAT; TGF

Indexed keywords

AFLIBERCEPT; AKB 9778; ALANINE AMINOTRANSFERASE; ALLOPURINOL; ANGIOGENESIS INHIBITOR; ATRASENTAN; AVOSENTAN; BARDOXOLONE METHYL; BARICITINIB; BEVACIZUMAB; BINDARIT; GKT 137831; IRBESARTAN; LOSARTAN; OXIDOREDUCTASE INHIBITOR; PARICALCITOL; PENTOXIFYLLINE; PIRFENIDONE; PLACEBO; RANIBIZUMAB; RUBOXISTAURIN; SPIRONOLACTONE; SULODEXIDE; UNCLASSIFIED DRUG; JANUS KINASE; STAT PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMINURIA; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DIABETIC MACULAR EDEMA; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; ESTIMATED GLOMERULAR FILTRATION RATE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPOMAGNESEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MUSCLE SPASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULARIZATION; ANIMAL; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHIES; METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; DIABETIC NEPHROPATHIES; HUMANS; JANUS KINASES; KIDNEY FAILURE, CHRONIC; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84944040027     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-015-0685-3     Document Type: Review

References (64)

1. Tazo Z, Shia A, Zhao J. Epidemiological perspectives of diabetes. Cell Biochem Biophys. 2015.
2. Saran R, Li Y, Robinson B, et al. US Renal Data System 2014 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2015;66(1 suppl 1):S1–306.
3. Chawla V, Bijan R. Non-proteinuric Diabetic Nephropathy. Curr Diab Rep. 2014; 14–529.
4. Messent JW, Elliot TG, Hill RD, et al. Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study. Kidney Int. 1992;41:836–9.
5. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137–88.
6. de Boer IH, Rue TC, Hall YN, et al. Temporal trends in prevalence of diabetic kidney disease in the United States. JAMA. 2011;305(24):2532–9.
7. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.
8. UK Propspective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. (UKPDS 33). Lancet. 1998;352:837–53.
9. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60(5):850–86.
10. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.
11. American Diabetes Association. Standards of medical care in diabetes—2015. Diabetes Care. 2015;38 suppl 1:S1–93.
12. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic enphroatphy. N Engl J Med. 2013;369:1892–903.
13. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both in people at high vascular risk (the ONTARGET study): a multicenter, randomised, double-blind, controlled trial. Lancet. 2008;372:547–53.
14. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):2204–13.
15. Sato A, Hayashi K, Naruse M, et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003;41:64–8.
16. Rossing K, Schoedt K, Smidt U, et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy. Diabetes Care. 2005;28:2106–211.
17. Bianchi S, Bigazzi R, Campese V, et al. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis. 2005;46:45–51.
18. Zoja C, Benigni A, Remuzzi G. The Nrf2 pathway in the progression of renal disease. Nephrol Dial Transplant. 2014;29:i19–24.
19. Aminzadeh MA, Reisman SA, Vziri ND, et al. The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuate oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease. Xenobiotica. 2014;44:570–8.
20. Pergola P, Raskin P, Toto P, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med. 2011;365:327–36.
21. Chin M, Reisman S, Bakris G, et al. Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes and stage 4 chronic kidney disease treated with Bardoxolone Methyl. Am J Nephrol. 2014;39:499–508.
22. McCormick B, Sydor A, Akbari A, et al. The effects of pentoxifylline on proteinuria in diabetic kidney diseaes: a meta-analysis. Am J Kidney Dis. 2008;52:454–63.
23. Navarro-Gonzalez J, Mora-Fernandez C, Muros de Fuentes M, et al. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. J Am Soc Nephrol. 2015;26:220–9. In this study, the addition of pentoxifylline to RAS blockade demonstrated reduction in albuminuria and slowed decreased in eGFR.
24. Perkins RM, Aboudara MC, Uy AL, et al. Effect of pentoxifylline on GFR decline in CKD: A pilot, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis. 2009;53:606–16.
25. Evcimen ND, King GL. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res. 2007;55:498–510.
26. Koya D, Haneda M, Nakagawa H, et al. Amelioration of accelerated diabetic mesangial expansion by treatment with PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J. 2000;14(3):439–47.
27. Tuttle KR, Bakris GL, Toto JB, et al. The effects of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care. 2005;28:2686–90.
28. Gilbert RE, Kim SA, Tuttle GL, et al. Effects of ruboxistuarin on urinary transforming growth factor-b in patients with diabetic nephropathy and type 2 diabetes. Diabetes Care. 2007;30:995–6.
29. Tuttle KR, McGill JB, Haney DJ, et al. Kidney outcomes in long-term studies of ruboxistuarin for diabetic eye disease. Clin J Am Soc Nephrol. 2007;2:631–6.
30. Tuttle KR, Bastyr III JB, McGill CL, et al. Albuminuria and kidney function in a long-term study of ruboxistaurin for diabetic neuropathy. J Am Soc Nephrol. 2007;2(4):631–6.
31. Cho ME, Smith DC, Branton MH, et al. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2007;2:906–13.
32. Sharma K, Ix JH, Mathew AV, et al. Pirfenidone for diabetic nephropathy. J Am Soc Nephrol. 2011;22:1144–51.
33. Kanamori H, Matsubara T, Mima A, et al. Inhibition of MCP-1/CRR2 pathway ameliorates the development of diabetic nephropathy. Biochem Biophys Res Commun. 2007;360:727–7.
34. Tesch GH. MCP-1/CLL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol. 2008;294:F697–701.
35. Ruggenenti P, Negarim M. Effects of MCP-1 inhibition by bindarit therapy in type 2 diabetes subjects with micro- or macro- albuminuria. J Am Soc Nephrol. 2010: 21.
36. Ble A, Mosca M, Loretto GD, et al. Antiproteinuric effect of chemokine C-C motif ligand 2 inhibition in subjects with acute proliferative lupus nephritis. Am J Nephrol. 2011;34(4):367–72.
37. Gambaro G, Cavazzana AO, Luzi P, et al. Glycosasminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int. 1992;42:285–91.
38. Gambaro G, Venturini AP, Noonan DM, et al. Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int. 1994;46:797–806.
39. Ceol M, Nerlich A, Baggio B, et al. Increased glomerular expression α1(IV) collagen expression and deposition in long-term diabetic rats is prevented by chronic glycosaminoglycan treatment. Lab Investig. 1996;74:484–95. In this study, atrasentan (a selective endothelin A receptor antagonist) with RAS inhibition successfully reduced albuminuria in type 2 diabetic nephropathy and thus may improve renal outcomes.
40. Ceol M, Gambaro G, Sauer U, et al. Glycosaminoglycan therapy prevents TGF- β 1 overexpression and pathologic changes in renal tissue of long-term diabetic rats. J Am Soc Nephrol. 2000;11:2324–36.
41. Van den Hoven MJ, Rops AL, Bakker MA, et al. Increased expression of heparanase in overt diabetic nephropathy. Kidney Int. 2006;70:2100–8.
42. Gambaro G, Kinalska I, Oksa A, et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol. 2002;13:1615–25.
43. Lewis EJ, Lewis JB, Greene T, et al. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis. 2011;58:729–36.
44. Packham DK, Wolfe R, Reutens AT, et al. Sulodexide fails to demonstrate renoprotective in overt type 2 diabetic nephropathy. J Am Soc Nephrol. 2012;23:123–30.
45. Wenzel R, Littke T, Kuranoff S, et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Neprol. 2009;20:655–64.
46. Mann JF, Green D, Jamerson K, et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol. 2010;21:527–35.
47. Kohan DE. Addition of atrasetan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol. 2011;58:763–72.
48. Zoppini G, Targher G, Chonchol M, et al. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care. 2010;35:99–104.
49. Kang DH, Park SK, Lee IK, et al. Uric acid- induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005;16:3553–62.
50. Siu YP, Leung KT, Tong MK, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:51–9.
51. Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effects of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5(8):1388–93.
52. Maahs DM, Caramori ML, Cherney DZI, et al. Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL). Curr Diab Rep. 2013;13(4):550–9.
53. Sanchez-Nino MD, Bozic M, Cordoba-Lanus E, et al. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. Am J Physiol Renal Physiol. 2012;302:F647–57.
54. de Zeeuw D, Agrawal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetic nephropathy (VITAL study): a randomised controlled trial. Lancet. 2010;367:1543–51.
55. The Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193–120.
56. Koh GY. Orchestral actions of angiopoeitin-1 in vascular regeneration. Trends Mol Med. 2013;19(1):31–9.
57. Aerpio therapeutics initiates phase 2 study of tie2 activator AKB-9778 for the treatment of diabetic macular edema. Aerpio Therapeutics. February 13, 2014. Web. August 3, 2015. .
58. Jeansson M, Gawlik A, Anderson G, et al. Angiopoeitin-1 is essential in mouse vasculature during development and in response to injury. J Clin Invest. 2011;121(6):2278–89.
59. Giacoo F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058–70.
60. Gray SP, Di Marco E, Okabe J, et al. NADPH oxidase 1 plays a role in diabetes mellitus-accelerated atherosclerosis. Circulation. 2013;127(18):1888–902.
61. Ortiz-Muñoz, Lopez-Parra V, Lopez-Franco O, et al. Suppressors of cytokine signaling abrogate diabetic nephropathy. J Am Soc Nephrol. 2010;21(5):763–72.
62. Walsh DW, Roxburgh SA, McGettigan P, et al. Co-regulation of Gremlin and Notch signaling in diabetic nephropathy. Biochim Biophys Acta. 2008;1782(1):10–21.
63. Marrero MB, Banes-Berceli AK, Stern DM, et al. Role of JAK/STAT signaling pathway in diabetic nephropathy. Am J Physiol Renal Physiol. 2006;290(4):F762–8.
64. Wang X, Shaw S, Amiri F, et al. Inhibition of the Jak/STAT signaling pathway prevents the high glucose-induced increase in tgf-beta and fibronectin synthesis in mesangial cells. Diabetes. 2002;51(12):3505–9.